Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  CARDIAC BIOMARKERS
A Global Strategic Business Report

This report analyzes the worldwide markets for Cardiac Biomarkers in Millions of US$. The market is analyzed by Location-wise (Clinical Laboratory Testing, and Point-of-Care Testing) and by Assay type-wise (Acute Myocardial Infarction (AMI) Tests (Creatine Kinase-MB (CK-MB), Cardiac Troponin, & Myoglobin), and Congestive Heart Failure (CHF) Tests (BNP &NT-proBNP)). The report provides separate omprehensive analytics for the US, Europe, and Rest of the World. Annual forecasts are provided for each region for the period of 2006 through 2015. A five-year historic analysis is also provided for these markets. The report profiles 78 companies including many key and niche players worldwide such as Abbott Diagnostics, Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biomérieux, Inverness Medical Innovations, Inc., LifeSign LLC, Nanogen Inc., Ortho-Clinical Diagnostics, Inc., Oxis International, Inc., Prognostix, Inc., Response Biomedical Corp., Roche Diagnostics Corp., and Siemens Healthcare Diagnostics, Inc..Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1632  PAGES:    432
PRICE:    $3950  DATE:       February 2009
COMPANIES:  78  MARKET DATA TABLES:   132
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  CARDIAC BIOMARKERS (Complete Report) Pages : 432   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY62$2250
  1. Industry Review.....II-16 $600  
   Cardiovascular Diseases: Leading cause of Mortality Worldwide.....II-1
Table 1: Region-wise Incidence & Prevalence of Cardiovascular Diseases in 2006.....II-1
Basic Topologies of Cardiovascular Diseases.....II-1
1$300
   Fast and Accurate Diagnosis – Reduce Unnecessary Healthcare Costs.....II-2
Cardiac Biomarkers - Making Diagnosis Easier and Quicker.....II-2
1$100
   What is a Cardiac Marker:.....II-3
Necessity of a Cardiac Marker Assay Test.....II-3
How it works?.....II-3
1$100
   Major Cardiac Markers and their Properties.....II-4
Market Analysis.....II-4
1$100
   Market Trends.....II-5
Strong Demand for Risk Assessment Markers.....II-5
Intense Competition among Players in the Cardiac Diagnostics Market.....II-5
The Future of Cardiac Marker POCT Segment.....II-5
1$100
   Need for Early Detection Markers.....II-6
Rapid Turnaround time: A Crucial Parameter for POC Testing Kits.....II-6
1$100
  2. Competitive Analysis.....II-72 $200  
   Siemens Healthcare becomes the leader, after a series of Acquisitions.....II-7
Product Portfolio of Bayer and Dade Behring.....II-7
2$200
  3. Cardiac Markers and Myocardial Infarction.....II-96 $600  
   Chain Reaction After an Event of MI.....II-9
Action Plan after an Event of MI.....II-9
1$100
   Protocol for Conducting AMI Markers Tests.....II-10
Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations.....II-10
Creatine Kinase – The Traditional Gold Standard, Loosing Sheen.....II-10
1$100
   Market and Forecasts:.....II-11
Isomers.....II-11
Kinetics.....II-11
Purpose of Test and When to Order.....II-11
Evaluation.....II-11
Points to remember.....II-11
1$100
   Cardiac Troponin – Taking Over from CK-MB.....II-12
Market and Forecast.....II-12
Overview.....II-12
Troponin Tissue-Specific Subtypes.....II-12
1$100
   Other Diseases.....II-13
Uses of Troponin Tests.....II-13
New Advanced High-sensitivity (Hs) Cardiac Troponin Tests.....II-13
Myoglobin.....II-13
1$100
   Purpose of Test and When to Order.....II-14
Testing and Evaluation.....II-14
Points to Remember.....II-14
Market and Forecast.....II-14
1$100
  4. Cardiac Markers and Congestive Heart Failure (CHF).....II-155 $500  
   Key Facts.....II-15
BNP (B-type Natriuretic Peptide).....II-15
1$100
   NT-proBNP (N-terminal proBNP).....II-16
Purpose of Tests and When to Order.....II-16
Testing and Evaluation.....II-16
Points to Remember.....II-16
1$100
   Market and Forecast.....II-17
Market Characteristics.....II-17
1$100
   Choosing the Right BNP and NT proBNP Assay Kit in the Market.....II-18
Evolution of BNP and NT proBNP Market.....II-18
1$100
   NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with
  Reduced Kidney Function.....II-19
1$100
  5. Stroke Biomarkers - A Review.....II-205 $500  
   Player Initiatives.....II-201$100
   Other Important Cardiac Biomarkers.....II-21
Homocysteine.....II-21
C-Reactive Protein.....II-21
1$100
   Plasminogen Activator Inhibitor-1.....II-22
D-Dimer.....II-22
Thrombus Precursor Protein.....II-22
Potential Future Cardiac Biomarkers.....II-22
3$300
  6. Cardiac Biomarker Testing in Clinical Laboratories.....II-251 $100  
   Market and Forecast.....II-25
Leading Players in Laboratory Cardiac Markers.....II-25
1$100
  7. Cardiac Biomarkers at Point-of-Care Testing.....II-262 $200  
   Market and Forecast.....II-261$100
   Major Players Operating in the Cardiac Markers POCT Segment.....II-27
Cardiac Markers Point-of-Care testing (POCT) Segment: Major Players & Their Operating
  Brands......II-27
1$100
  8. Strategic Corporate Developments.....II-2810 $700  
   Response Biomedical Signs Partnership Agreement with Roche.....II-28
Nanogen and Elitech Plans to Merge.....II-28
Compugen Announces Discovery of Troponin I Biomarker Variant, Inks Agreement with
  Biosite.....II-28
1$100
   Inverness Acquires Biosite.....II-29
Siemens Acquires Diagnostic Division of Bayer Healthcare.....II-29
Siemens Announces Acquisition of Dade Behring.....II-29
Beckman Collaborates in CVD Related Research Projects.....II-29
1$100
   Dade Behring Receives Sublicense to New Cardiac Marker.....II-30
Inverness Acquires Cholestech.....II-30
Response Biomedical Secures Clearance to Market RAMP® NT-proBNP Test.....II-30
Acrongenomics Collaborates with Molecular Vision and Pearson Matthews.....II-30
1$100
   BG Medicine Obtains Rights to Develop Tests for Congestive Heart Failure.....II-31
Nanogen Gains US Reissue Patent for Combined Use of Biomarkers for CHF
  Diagnosis.....II-31
Nanogen Secures FDA Approval for CHF NT-proBNP EDTA Plasma Test.....II-31
Roche Diagnostics Secures FDA Approval for Roche Elecsys® proBNP Test.....II-31
1$100
   Nanogen Acquires Rapid Cardiac Immunoassay Test Businesses of SDI.....II-32
Response Biomedical Starts Clinical Trials of the RAMP NT- proBNP Test.....II-32
Procter and Gamble, Inverness to Form JV for Consumer Diagnostics.....II-32
1$100
   Roche Diagnostics Grants Rights for NT- proBNP to Mitsubishi Kagaku Latron.....II-33
Bayer Healthcare Receives FDA Approval for Troponin-I-Test Tnl-Ultra.....II-33
MKI Obtains EU Approval and CE Mark for Four Cardiac Markers.....II-33
Dade Behring Grants PIGF Rights to Abbott.....II-33
OXIS International Acquires Biocheck.....II-33
1$100
   Wampole, Roche collaborate on Ischemia Modified Albumin Test.....II-34
Nanogen Extends Point-of-Care Diagnostic Tests Distribution in Europe.....II-34
Abbott, Cleveland Clinic Agrees to Develop MPO Cardiac Test.....II-34
Response Biomedical Receives Non-exclusive Rights to Roche’s Cardiac Markers.....II-34
1$100
   Roche Diagnostics Grants Rights to Response Biomedical for Troponin T and NT-
  proBNP.....II-35
Inverness to Acquire Ischemia Technologies.....II-35
1$100
   Roche Diagnostics Grants Rights for NT- proBNP to bioMerieux.....II-36
Roche Confers Rights of NT-proBNP to Ortho-Clinical Diagnostics.....II-36
Dade Behring Grants CRP Sublicense to Roche Diagnostics.....II-36
Roche Awards Non Exclusive Rights of NT-proBNP marker to DPC.....II-36
1$100
   Abbott Gains Approval for CK-MB Test in the US.....II-37
i-STAT Gains Approval for Troponin I Test from US FDA.....II-37
1$100
  9. Product Launches/Developments/Approvals.....II-386 $400  
   Response Bags FDA Clearance for RAMP® NT-proBNP Test.....II-38
bioMérieux Rolls out VIDAS® NT-proBNP.....II-38
Roche Diagnostics Introduces Cobas-H-232 Handheld Cardiac Marker System.....II-38
OXIS Discovers a Unique Diagnostic Biomarker for Cardiovascular Disease.....II-38
1$100
   Ortho-Clinical Presents Sensitivity Troponin I Test, VITROS Troponin I ES.....II-39
bioMerieux Unveils ‘VIDAS® Troponin I Ultra’.....II-39
Roche Elecsys proBNP Assay Secures FDA Clearance.....II-39
1$100
   Bayer Launches New Tnl-Ultra™ Troponin Assay on ADVIA Centaur® CP Immunoassay
  system.....II-40
Ortho-Clinical Diagnostics Receives FDA Clearance for VITROS NT-proBNP Assay.....II-40
Dade Behring Launches CardioPhase® hsCRP Test.....II-40
1$100
   Diagnostic Products Corporation to Market NT-proBNP Outside US.....II-41
Dade Behring Introduces Homocysteine Assay for BN™ System.....II-41
Biosite Develops Triage® Cardio ProfilER™ Panel.....II-41
A Breakthrough Biochip Array System for MI.....II-41
1$100
   FDA Approves Emergency Department Diagnostic Test from Biosite.....II-42
Response Biomedical Obtains Regulatory Clearance for RAMP®.....II-42
Response Biomedical Gains US FDA Approval for 3rd RAMP® Test.....II-42
CLINIQA Rolls Out Liquid Stable Cardiac Marker Controls.....II-42
1$100
   Abbott Releases AxSYM® Troponin-I ADV Assay in World Markets.....II-43
1$100
  10. Focus on Select Global Players.....II-445 $500  
   Abbott Diagnostics (USA).....II-44
Ani Biotech Oy (Finland).....II-44
Axis-Shield PoC (UK).....II-44
1$100
   Beckman Coulter, Inc. (USA).....II-45
biomérieux (France).....II-45
Inverness Medical Innovations, Inc. (USA).....II-45
1$100
   LifeSign LLC (USA).....II-46
Nanogen Inc. (USA).....II-46
Ortho-Clinical Diagnostics, Inc. (USA).....II-46
1$100
   Oxis International, Inc. (USA).....II-47
Prognostix, Inc. (USA).....II-47
Response Biomedical Corp. (Canada).....II-47
Roche Diagnostics Corp. (USA).....II-47
1$100
   Siemens Healthcare Diagnostics, Inc. (USA).....II-48
1$100
  11. Global Market Perspective.....II-49   
   Table 2: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-491$300
   Table 3: World Historic Review Analysis for Cardiac Biomarkers by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-50

Table 4: World 10-Year Perspective for Cardiac Biomarkers by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-50
1$300
   Table 5: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-511$300
   Table 6: World Historic Review Analysis for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-52

Table 7: World 10-Year Perspective for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-52
1$300
   Table 8: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-531$300
   Table 9: World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-54

Table 10: World 10-Year Perspective for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region – US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-54
1$300
   Table 11: World Recent Past, Current & Future Analysis for CK-MB Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-551$300
   Table 12: World Historic Review Analysis for CK-MB Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-56

Table 13: World 10-Year Perspective for CK-MB Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-56
1$300
   Table 14: World Recent Past, Current & Future Analysis for Cardiac Troponin Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-571$300
   Table 15: World Historic Review Analysis for Cardiac Troponin Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-58

Table 16: World 10-Year Perspective for Cardiac Troponin Assay Test by Geographic Region– USA, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-58
1$300
   Table 17: World Recent Past, Current & Future Analysis for Myoglobin Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-591$300
   Table 18: World Historic Review Analysis for Myoglobin Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-60

Table 19: World 10-Year Perspective for Myoglobin Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-60
1$300
   Table 20: World Recent Past, Current & Future Analysis for BNP & NT-proBNP Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-611$300
   Table 21: World Historic Review Analysis for BNP & NT-proBNP Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-62

Table 22: World 10-Year Perspective for BNP & NT-proBNP Assay Test by Geographic Region– US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-62
1$300
III. MARKET59$1950
  1. The United States.....III-125 $1675  
   A. Market Analysis.....III-1
Cardiovascular Diseases in US: A Review.....III-1
Table 23: The US Disease Statistics for Coronary Heart Disease (CHD) & Myocardial Infarction (MI).....III-1
1$150
   Table 24: The US Prevalence of Coronary Heart Disease (CHD) as a Percentage of Total Population by Age-group & Sex, in 2005 - 06. (includes corresponding Graph/Chart).....III-2

Table 25: The US Annual Number of New & Recurrent Adults diagnosed with Heart Attack by Age & Sex in the Recent Past (includes corresponding Graph/Chart).....III-2

Table 26: The US Disease Statistics for Heart Failure.....III-2
1$150
   Table 27: The Annual Number of Americans Diagnosed with Heart Failure as 'per 1000 persons' by Age & Sex, in the Recent Past (includes corresponding Graph/Chart).....III-3
30% Fall in Number of Deaths due to Heart Diseases & Strokes Over Last
  Decade.....III-3
Senior Citizens at High Risk for Heart Failure.....III-3
1$150
   CHF Biomarkers to Spearhead the US market.....III-4
US Cardiac Markers POCT Segment.....III-4
1$75
   Table 28: US AMI (Acute Myocardial Infarction) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart).....III-5

Table 29: US CHF (Congestive Heart Failure) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart).....III-5

Table 30: US Laboratory Testing Segment: Market Share by Revenue held by Major Players (Abbott, Dade Behring, Bayer, Beckman Coulter, Roche, Ortho-clinical, and Others) in 2001 (includes corresponding Graph/Chart).....III-5
1$150
   Product Launches/Approvals/Developments.....III-64$300
   Strategic Corporate Developments.....III-107$525
   Key Players.....III-17
Abbott Diagnostics.....III-17
Beckman Coulter, Inc......III-17
1$75
   diaDexus, Inc......III-18
Inverness Medical Innovations, Inc......III-18
LifeSign LLC.....III-18
Nanogen Inc......III-18
1$75
   Ortho-Clinical Diagnostics, Inc......III-19
Oxis International, Inc......III-19
Prognostix, Inc......III-19
1$75
   Roche Diagnostics Corp......III-20
Siemens Healthcare Diagnostics, Inc......III-20
1$75
   B. Market Analytics.....III-21
Table 31: US Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-21

Table 32: US Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-21
1$150
   Table 33: US 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015.....III-221$150
   Table 34: US Recent Past, Current and Future Analysis for Cardiac Markers by Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-231$150
   Table 35: US Historic Review Analysis for Cardiac Markers by Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-241$150
   Table 36: US 10-Year Perspective for Cardiac Markers by Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015 (includes corresponding Graph/Chart).....III-25
1$150
  2. Europe.....III-2611 $1000  
   A. Market Analysis.....III-26
European Cardiovascular Diseases Fact Sheet.....III-26
Evolution of the European Cardiac Risk Markers Market.....III-26
1$75
   Cardiac Markers in Primary Care Sector.....III-27
Product Launches/Approvals/Developments.....III-27
1$75
   Strategic Corporate Developments.....III-281$75
   B. Market Analytics.....III-29
Table 37: European Recent Past, Current and Future Analysis for Cardiac Markers by Region – France, Germany, Italy, UK, and ‘Rest of Europe’ Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-29
1$150
   Table 38: European Historic Review Analysis for Cardiac Markers by Region – France, Germany, Italy, UK, and ‘Rest of Europe’ Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-301$150
   Table 39: European 10-Year Perspective for Cardiac Markers by Region – France, Germany, Italy, UK, and ‘Rest of Europe’ Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015 (includes corresponding Graph/Chart).....III-311$150
   Table 40: European Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-32

Table 41: European Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-32
1$150
   Table 42: European 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015.....III-331$150
   Table 43: European Recent Past, Current and Future Analysis for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-341$150
   Table 44: European Historic Review Analysis for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-351$150
   Table 45: European 10-Year Perspective for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015 (includes corresponding Graph/Chart).....III-36
1$150
  2a. France.....III-374 $300  
   A. Market Analysis.....III-37
Product Launches/Approvals/Developments.....III-37
1$75
   Strategic Corporate Developments.....III-38
Key Players.....III-38
1$75
   B. Market Analytics.....III-39
Table 46: French Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-39

Table 47: French Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-39
1$150
   Table 48: French 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015.....III-40
1$150
  2b. Germany.....III-412 $225  
   A. Market Analysis.....III-41
Rennesens GmbH.....III-41
B. Market Analytics.....III-41
Table 49: German Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-41
1$150
   Table 50: German Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-42

Table 51: German 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015......III-42
1$150
  2c. Italy.....III-432 $225  
   Market Analysis.....III-43
Table 52: Italian Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-43
1$150
   Table 53: Italian Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-44

Table 54: Italian 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015.....III-44
1$150
  2d. United Kingdom.....III-454 $375  
   A. Market Analysis.....III-45
UK Cardiovascular Diseases Fact Sheet.....III-45
1$75
   Table 55: The UK’s Healthcare Costs of Cardio Vascular Diseases (CVD), Coronary Heart Diseases (CHD) & Strokes in 2006 (includes corresponding Graph/Chart).....III-46
Siemens and PETNET Pharmaceuticals Acquire PETNET’s New England Operations.....III-46
Key Players.....III-46
Axis-Shield PoC.....III-46
1$150
   B. Market Analytics.....III-47
Table 56: UK Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-47
1$150
   Table 57: UK Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-48

Table 58: UK 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015.....III-48
1$150
  2e. Rest of Europe.....III-493 $225  
   A. Market Analysis.....III-49
Key Player.....III-49
Ani Biotech Oy.....III-49
1$75
   B. Market Analytics.....III-50
Table 59: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-50
1$150
   Table 60: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-51

Table 61: Rest of Europe 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015.....III-51
1$150
  3. Rest of the World.....III-528 $675  
   A. Market Analysis.....III-52
Evolution of BNP Test market in Japan.....III-52
Product Launches/Approvals/Developments.....III-52
1$75
   Strategic Corporate Developments.....III-531$75
   Key Players.....III-54
Response Biomedical Corporation (Canada).....III-54
Sekisui Medical Co. Ltd. (Japan).....III-54
Shionogi and Co. Ltd. (Japan).....III-54
1$75
   B. Market Analytics.....III-55
Table 62: Rest of the World Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-55
1$150
   Table 63: Rest of the World Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-56

Table 64: Rest of the World 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015.....III-56
1$150
   Table 65: Rest of the World Recent Past, Current and Future Analysis for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-571$150
   Table 66: Rest of the World Historic Review Analysis for Cardiac Markers by Assay Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-581$150
   Table 67: Rest of the World 10-Year Perspective for Cardiac Markers by Test Type – AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015 (includes corresponding Graph/Chart).....III-591$150
IV. COMPETITIVE LANDSCAPE 296$995
  
Total Companies Profiled: 78 (including Divisions/Subsidiaries - 96 )

Region/Country                 Players


The United States                40
Canada                            5
Japan                             5
Europe                           25
     France                       6
     Germany                      2
     The United Kingdom           7
     Italy                        1
     Spain                        1 
     Rest of Europe               8
Asia-Pacific (Excluding Japan)   18
Latin America                     1
Africa			          
Middle East                       2
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.